Crystal Voegeli
Primary Care · Port Arthur, TXNPI 1295173722
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 222 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 34.9% of the total. Among primary care clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 222 payments — averaging $14.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$916
- Lilly USA, LLC$170
- GSK$143
- Amgen$115
- AstraZeneca$113
- plus $700 from 19 others
What the payments were for
- Food & beverage$3,313100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 83 | $1,157 |
| Novo Nordisk | 71 | $916 |
| Lilly USA, LLC | 10 | $170 |
| GSK | 8 | $143 |
| Amgen | 6 | $115 |
| AstraZeneca | 7 | $113 |
| Bayer | 5 | $101 |
| Biohaven Pharmaceuticals, Inc. | 1 | $81 |
| Merck | 4 | $61 |
| Axsome Therapeutics, Inc. | 3 | $55 |
| Sanofi-aventis U.S. LLC | 3 | $52 |
| Phathom Pharmaceuticals, Inc. | 3 | $47 |
| Idorsia Pharmaceuticals US Inc | 3 | $47 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Genentech USA, Inc. | 3 | $32 |
| Neurocrine Biosciences, Inc. | 1 | $29 |
| Lundbeck LLC | 1 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Optinose US, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Pfizer | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
How this compares
$3,313 in reported general payments places this provider in the 90th percentile of 563 primary care providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 113 | $162,179 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $42,925 |
| EliquisApixaban | 47 | $36,001 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $29,238 |
| FarxigaDapagliflozin Propanediol | 25 | $28,381 |
| MounjaroTirzepatide | 24 | $26,210 |
| LinzessLinaclotide | 18 | $18,338 |
| XareltoRivaroxaban | 17 | $17,044 |
| JardianceEmpagliflozin | 12 | $13,752 |
| Repatha SureclickEvolocumab | 16 | $10,828 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 132 | $3,538 |
| Gabapentin | 171 | $2,719 |
| Duloxetine Hcl | 61 | $2,692 |
| Atorvastatin Calcium | 193 | $2,564 |
| Rosuvastatin Calcium | 156 | $2,537 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $916 | $162,179113 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $113 | $57,61953 claims |
| GSKTrelegy Ellipta | $143 | $42,92557 claims |
| PfizerEliquis | $15 | $36,00147 claims |
| Lilly USA, LLCMounjaro | $170 | $26,21024 claims |
| AbbVieLinzess | $1,157 | $18,33818 claims |
| Boehringer IngelheimJardiance | $15 | $13,75212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 563 primary care providers in Texas.
Other primary care in Port Arthur
- Mary GibbensHouston$42K
- Phillip GulleySan Antonio$23K
- Herbert BautistaDallas$14K
- Brandi JoynerLongview$12K
- Steven ParisAustin$10K
- Hope OdomCollege Station$10K
- Arlena GraysTomball$9K
- Charlotte BallardSan Antonio$9K
- Hannah LancasterMcKinney$9K
- Jacqueline MilesGrand Prairie$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.